Table 1.
Patient characteristics.
| PDO line | EACorg000 | EACorg002 | EACorg006 | EACorg011 |
|---|---|---|---|---|
| Patient No | 134 | 153 | 155 | 168 |
| Age | 76 | 70 | 79 | 63 |
| Gender | M | M | M | M |
| Pre-treatment Stage | T2N0M0 | T3N1Mx | T3N2M0 | T3N1M0 |
| Histology | Adenocarcinoma | Adenocarcinoma with signet cell features | Adenocarcinoma | Adenocarcinoma |
| Differentiation | Moderate | Poor | Moderate | Poor |
| Neoadjuvant Treatment | SC | FOLFOX + PBT | SC | SC |
| Clinical response | NR | PR | PR | PR |
| Pathological response | PR | PR | PR | PR |
| Post-treatment stage (pathological) | T1bN0M0 | T3N0M0 | T2N2M0 | T3N0M0 |
SC standard of care, platinum-based doublet with paclitaxel and radiation therapy, PBT proton beam therapy, PR/NR partial response/no response, FOLFOX Folinic acid-5-Fluorouracil-Oxaliplatin.